Thomas A. Zelniker

Statistics

Publications

Citations

10.1K

H-Index

Active since

2011

Affiliations

Thrombolysis in Myocardial Infarction Study Group(Current)

Brigham and Women's Hospital

Medical University of Vienna

Harvard University

Heidelberg University

Thomas A. Zelniker is an author at Thrombolysis in Myocardial Infarction Study Group specializing in medicine, cardiology, and cardiovascular disease.

ORCID

Publications per year

2011–2023

Publications

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Ofri Mosenzon, Stephen D. Wiviott, Avivit Cahn et al. · The Lancet Diabetes & Endocrinology · 2019 · 675 citations · Full text

Medicine, Nephrology, Pharmacology +14

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Eri Kato, Michael G. Silverman, Ofri Mosenzon et al. · Circulation · 2019 · 563 citations

Medicine, Cardiology, Pharmacology +15

Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus

Thomas A. Zelniker, Marc P. Bonaca, Remo H.M. Furtado et al. · Circulation · 2020 · 452 citations · Full text

Medicine, Cardiology, Pharmacology +17

Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation

Steffen Desch, Anne Freund, Michael Behnes et al. · New England Journal of Medicine · 2021 · 359 citations · Full text

Medicine, Cardiology, Acute Care Medicine +11

1–5 of 43